Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000239 · ClinicalTrials.gov registry record · Phase 2
Buprenorphine Pharmacology Related to Addiction Treatment - 21
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00000239: Completed Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT00000239 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000239, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to examine if chronic buprenorphine administration will generate supersensitivity to opiates.
Interventions
- DRUG Buprenorphine
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
What the finished NCT00000239 record still lists
NCT00000239 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Buprenorphine is the first listed.
NCT00000239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00000239 about?
NCT00000239 is a clinical study titled "Buprenorphine Pharmacology Related to Addiction Treatment - 21". The purpose of this study is to examine if chronic buprenorphine administration will generate supersensitivity to opiates.
What is the current status of trial NCT00000239?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00000239?
The interventions under investigation include: Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT00000239?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.